Phaseline

Companies › Hummingbird Bioscience

Hummingbird Bioscience: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HMBD-501
HER3-targeted antibody-drug conjugate
ERBB3Phase 1Melanoma (Skin)Jul 2027
HMBD-001
Anti-HER3 monoclonal antibody
ERBB3Phase 1Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Bladder CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05057013HMBD-001Phase 1Bladder CancerOncologyNov 2025
NCT06956690HMBD-501Phase 1Melanoma (Skin)OncologyJul 2027
NCT05910827HMBD-001Phase 1Advanced or Metastatic Squamous Non-Small Cell Lung CancerOncologyDec 2027
NCT05919537HMBD-001Phase 1Non-Small Cell Lung CancerOncologyMar 2031

Targets

ERBB3 (2)

Companies with the same targets

Shanghai Institute Of Biological Products Daiichi Sankyo Salubris Biotherapeutics Merck & Co. (MSD) Partner Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.